Advertisement
Canada markets closed

  • S&P/TSX

    21,969.24
    +83.86 (+0.38%)
     

  • S&P 500

    5,099.96
    +51.54 (+1.02%)
     

  • DOW

    38,239.66
    +153.86 (+0.40%)
     

  • CAD/USD

    0.7316
    -0.0007 (-0.09%)
     

  • CRUDE OIL

    83.66
    +0.09 (+0.11%)
     

  • Bitcoin CAD

    86,018.77
    -2,365.93 (-2.68%)
     

  • CMC Crypto 200

    1,305.57
    -90.97 (-6.51%)
     

  • GOLD FUTURES

    2,349.60
    +7.10 (+0.30%)
     

  • RUSSELL 2000

    2,002.00
    +20.88 (+1.05%)
     

  • 10-Yr Bond

    4.6690
    -0.0370 (-0.79%)
     

  • NASDAQ

    15,927.90
    +316.14 (+2.03%)
     

  • VOLATILITY

    15.03
    -0.34 (-2.21%)
     

  • FTSE

    8,139.83
    +60.97 (+0.75%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

  • CAD/EUR

    0.6838
    +0.0017 (+0.25%)
     

Company News for May 13, 2021

Zacks Equity Research
·1 min read

  • Shares of Toyota Motor Corporation TM rose 0.8% after the company reported fourth-quarter fiscal 2021 earnings of $5.18 per share, beating the Zacks Consensus Estimate of $3.45.

  • Lucira Health, Inc.’s LHDX shares surged 44.2% after the company reported its Lucira CHECK IT COVID-19 test kit is now available on Amazon in the United States.

  • Shares of Second Sight Medical Products, Inc. EYES jumped 27.6% after the company disclosed two-year results of Orion study.

  • CVR Energy, Inc.’s CVI shares rose 8.5% after the company reported a $492 million special dividend and also said that it is interested in renewable fuels instead of buying another crude oil refinery.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Toyota Motor Corporation (TM) : Free Stock Analysis Report
 
CVR Energy Inc. (CVI) : Free Stock Analysis Report
 
Second Sight Medical Products, Inc. (EYES) : Free Stock Analysis Report
 
Lucira Health, Inc. (LHDX) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research